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Abstract: Objectives: The objective of this study was to evaluate bone reconstruction using xenograft
alone and associated with bone marrow aspirate concentrate (BMAC) and hyperbaric oxygen therapy.
Material and Methods: Twenty-four maxillary edentulous patients were randomly assigned into
three groups: Control group (CG)—xenograft bone alone (n = 8); Group 1 (G1)—xenogeneic bone
block combined with BMAC (n = 8), and Group 2 (G2)—xenogeneic bone block combined with
BMAC and hyperbaric oxygenation (n = 8). Bone biopsies were harvested 6 months after grafting.
Vital Mineralized Tissue (VMT), Non-vital Mineralized Tissue (NVMT), and Non-Mineralized
Tissue (NMT) were measured. Computed tomography was also performed on three occasions
T0 (preoperative), T4 (4 months postoperative), and T8 (8 months postoperative). The difference
between T4 and T8 values with respect to T0 was used to determine the thickness level gain after 4
and 8 months, respectively. Results: The tomographic evaluation did not show significant differences
between the groups either at 4 or at the 8 months postoperatively. Regarding the histomorphometric
analysis, CG had the lowest percentages of VMT (36.58 ± 9.56%), whereas G1 and G2 had similar
results (55.64 ± 2.83% and 55.30 ± 1.41%, respectively). Concerning NMT and NVMT levels, the
opposite was observed, with CG levels of 51.21 ± 11.54% and 11.16 ± 2.37%, G1 of 39.76 ± 11.48%
and 3.65 ± 0.87%, and G2 of 40.3 ± 11.48% and 4.10 ± 0.87%, respectively. Conclusions: The use of
bone block xenograft associated with BMAC resulted in a significant increase of bone neoformation
when compared to the xenograft alone, though hyperbaric oxygenation did not enhance the results.
Keywords: maxilla; bone marrow; hyperbaric oxygenation; bone xenograft
1. Introduction
Autologous bone grafting is regarded as the gold standard for reconstruction of bony defects.
The use of autologous bone grafts is a safe option to restore bone volume for implant supported
dental rehabilitations, with the added benefit provided by the osteogenic (by the osteoprogenitor
cells), osteoinductive (by the molecules that can induce osteogenic differentiations of local stem cells),
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and osteoconductive (by the scaffold that permits bone apposition) stimuli inherent of such tissues.
However, there are some issues that must be stated concerning this approach, such as morbidity of
the donor site, limited bone supply, and loss of bone volume during healing. Other options such
as synthetic, allograft, and xenogenic bone have also been used for bone regeneration purposes [1].
In this field, the xenogenic equine block biomaterial is a reasonable alternative to autologous grafting,
as it has been demonstrated to generate adequate levels of hard tissue gain in reconstructions of the
atrophic maxilla [2].
In recent years, an increasing interest in the use of bone marrow stem cells for bone regeneration
has been observed, since in vitro and in vivo experiments have shown highly promising results [3].
In addition to being able to give rise to blood cells, bone marrow may have the potential to induce
undifferentiated cells to differentiate into a variety of tissues, including bone and cartilage [4]. In this
scope, nowadays nanoscience is producing novel substitutes that could imitate the extra cellular matrix
conditions of these tissues [5].
The lack of cellularity observed in bone substitute biomaterials has been fuelling research into
the field of tissue engineering aiming at combining autologous osteogenic cells with osteoconductive
structures. In this context, bone marrow is one of the most widely used sources of autologous cells.
Bone marrow contains a series of cells with affinity for bone regeneration, such as undifferentiated
mesenchymal cells [6,7]. In addition, they also feature an angiogenic potential associated with vascular
endothelial growth factor [8], a highly desirable property for graft integration [9]. The process to
obtain a bone marrow aspirate concentrate (BMAC) increases the density of potentially osteogenic cells
within the bone graft, which has been explored in research to increase the osteoinductive potential
of fresh bone marrow cells [10]. Furthermore, puncture aspiration to harvest bone marrow cells
is relatively easier than harvesting autologous bone for grafting from the same donor site [11].
Hernigou et al. (2014) [12] compared the donor area complications when using bone marrow cells
obtained by aspiration from the iliac crest with the classical bone graft harvested from the iliac crest
and verified that complications with bone marrow aspiration was ten times less, and the complications
were clearly less severe. Therefore, BMAC has being considered a technique that can enhance the
potential of bone grafts procedures with minimal morbidity.
Another technique that is being related to an improvement in bone regeneration without the
morbidity related to the autogenous bone graft is the use of rh-BMP. However, despite the potential to
substitute the usage of autogenous bone graft in challenging situations such as clefts of the anterior
maxilla and reconstruction of large defects after tumor resection or osteonecrosis treatment, the use of
rh-BMP is also related to some issues (e.g., inconsistent or poor-quality bone formation, alteration of
osteoblast/osteoclast balance, and adverse facial edema) [13]. Therefore, some researchers, instead of
using non-physiological levels of growth factors, are focusing their studies in the autologous use of
bone marrow cells for bone regeneration purposes, which is the main goal of the present study.
Hyperbaric oxygen therapy consists in exposing the patient to 100% oxygen under high pressure.
This therapy is based on two physical laws and some biochemical processes that explain its mechanism
of action. The first, Henry’s law, according to which the amount of gas dissolved in a liquid (in this
case, oxygen in plasma) increases with the pressure exerted by this gas on that liquid. The second,
Boyle-Mariotti’s law, according to which the space occupied by a certain volume of gas will decrease
as pressure increases, i.e., gas volume shrinks under high pressure, whereas it expands with low
pressure [14]. The mechanism of action of hyperbaric oxygen therapy is the result of a combination of
factors. Leukocytes under hypoxia struggle to phagocytize bacteria, which is reversed when oxygen
tension is raised again. In addition, synthesis of collagen by fibroblasts increases with an enhanced
availability of oxygen. Postoperative hyperbaric oxygenation in bone grafting procedures has also
been associated with improvements in bone healing [15].
Therefore, it can be speculated that using both BMAC and hyperbaric oxygen in bone
augmentation procedures could maximize the regenerative results, which might have clinical
repercussions in the bone reconstruction field. Considering the aforementioned context, the aim
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of this study was to evaluate the effect of bone marrow aspirate concentrate combined with xenografts
on the treatment of the atrophic maxilla in patients submitted to hyperbaric oxygenation.
2. Materials and Methods
The surgical protocol for this study was analyzed and approved by the São Leopoldo Mandic
Dental School Ethics Committee (number 838.635/14).
The clinical procedures were undertaken with the understanding and written consent of each
patient and in full accordance with the ethical principles of the World Medical Association Declaration
of Helsinki (2013). Furthermore, the study was conducted in compliance with the Consolidated
Standards of Reporting Trials (CONSORT) statement, where applicable. Pregnant, diabetic, or
immunocompromised patients, as well as smokers and patients under any sort of medication that
could interfere with the surgical protocol or with bone metabolism were excluded from the study.
After applying these exclusion criteria, twenty-four maxillary edentulous patients with an a 2 to
3 mm anterior alveolar ridge thickness were selected from the outpatient dental clinic at Santa Monica
Medical Center (Erechim, Brazil), all of whom agreed to participate in this study and signed an
informed consent form prior to initiating treatment. All patients required a fixed rehabilitation (i.e.,
implants and a Branemark’s protocol rehabilitation).
The patients were assigned into three groups: Control group (CG)—xenogeneic bone blocks only
(n = 8); Group 1 (G1), in which patients received a xenograft combined with BMAC (n = 8); Group 2
(G2)—patients receiving xenogeneic bone blocks associated to BMAC and hyperbaric oxygenation
(n = 8). In all patients, collagen membranes were positioned over the xenogeneic bone blocks following
the principles of guided bone regeneration (GBR).
2.1. Bone Marrow Aspirate Concentrate (BMAC)
In an outpatient setting, 30 mL of bone marrow was harvested from the patients via puncture
aspiration of the iliac bone using an 11 G cannula (Terumo®, São Paulo, SP, Brazil) under local
anesthesia (2% xylocaine without vasoconstrictor) (Figure 1).
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The bone marrow aspirate was manipulated for bone marrow concentration using the BMAC2
kit (Terumo®, São Paulo, SP, Brazil), according to the manufacturer’s instructions. At the end of the
procedure, 4 mL of bone marrow aspirate concentrate was obtained (Figure 2a,b). This process was
done in all G2 G1 and G3 patients.
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2.2. Association of the Bone Marrow Aspirate Concentrate to t e Xenograft Blocks
The entire volume of BMAC was combined directly with the biomaterial by dripping until all
graft material was embedded (Figure 3). This process was done in all G2 G1 and G3 G2 patients.
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2.3. Surgical Technique for Bone Grafting
Local infiltration and regional block anesthesia was administered, followed by an incision in
the alveolar ridge to raise a mucoperiostal flap to the base of the nose to access the area to be
grafted. Subsequently, the remaining bone structure was decorticated using round burs. Bone grafts
(25 × 10 × 5) from equine origin (Bioteck, Italy) were adapted and fixed onto the bony defect using
one or two titanium screws (Neodent, Brazil) that measured 1.5 mm in diameter and 8.0 or 10.0 mm
in length (Figures 3 and 4). After bone blocks fixation, they were covered by a resorbable membrane
(Bioteck, Torino, Italy) and the flap was closed by using single sutures.
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2.4. Hyberbaric Oxygenation (HBO)
A specialist physician in hyperbaric medicine assessed the patients from the hyperbaric
oxygenation group (G2) to ensure their safety to undergo the procedure, which occurred 24 h after
bone grafting. The hyperbaric chamber used was a Multiplace nº 16251, model SR 10 (Ilma metalúrgica,
Indaiatuba—Sao Pablo, Brazil).
Briefly, each patient was accommodated into the chamber, which was pressurized with air
(21% oxygen) to 2.5 atmospheres (15 m deep), equivalent to 22 lbs. over approximately 12 min, during
which the patients performed the Valsalva maneuver to compensate for pressurization. After the
facemask was in place, 100% oxygen was administered.
Each session of hyperbaric oxygen therapy lasted between 100 and 120 min. During each session,
patients were given oxygen on three occasions, the first lasting 20 min, whereas the second and third
for 30 min. Patients were monitored throughout the session by a specially trained nursing technician.
Depressurization was performed gradually over 12 min, during which patients kept their
facemask on receiving 100% oxygen until the last 3 meters of pressure. Once depressurization was
complete, the chamber hatch was opened and the patient was released. In total, the patients underwent
a daily session of hyperbaric oxygenation for twenty days. This process was done in every G2 patients.
2.5. Bone Biopsies
For all patients, after six months of grafting, the osteotomy site was reopened (Figure 5) for
installation of dental implants, when bone samples were collected using a trephine drill (Figures 6
and 7), and subsequently fixed in 10% buffered formalin for histological analysis.
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2.6. isto orpho etric Evaluation
The biopsies ere fixed in 10 buffered for alin for 24 h and decalcified in 20 for ic acid for
three hours. They were then processed and embedded in paraffin. Five-micrometer sections were cut,
mounted on slides and stained for Masson’s trichrome. Images were captured using a Nikon Elipse Ci
microscope at 100× magnification coupled to an Infinity 1 digital camera (5 megapixel) (Lu enera Co.,
Nepean, ON K2E 8A7 Canada), and reproduced on a computer screen using the Infinity Analyze
software (Lumenera Co., Canada). Histomorphometry was performed using Image J (NIH) to quantify
the areas of vital mineralized tissue (VMT), non-mineralized tissue (NMT), and non-vital mineralize
tissue (NVMT) (Figures 8–10). The level of newly formed bone (i.e., VMT) was stated as the primary
outcome of this study.
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Figure 10. Histological view of NVMT (light red), VMT (dark red) and NMT (sparse tissue) from a
Group 2 G2) specimen, under 100× magnification (Masson’s trichrome).
2.7. Computed Tomographic (CT) Evaluation
Cone beam computed tomography (I-CAT Workstation, Cone Beam 3D, Imaging Sciences
International Hatfield, Rochester, NY, USA) of the maxilla of all patients was performed at 1 mm slices
on three occasions, namely T0 (preoperative), T4 (4 months after surgery), and T8 (8 months after
surgery). The images obtained were analyzed using XoranCATTM software, version 3.1.62 (Figures 11
and 12). Alveolar bone thickness was measured between the bony crest and a 15 m apical imaginary
line to the bo e crest, dividing the alveolar ridge into 3 × 5 mm thirds: Apical, middle, and coronary
(Figure 13). Bon thickness was measured from the mo t c tral point of e ch third. The average
value from the three measurements was then considered to calculate mineralized tissue gain, from T0
through to T4 and T8. Statistical analysis was performed on bone gain at four months by subtracting
the mean T0 value from the T4 value, and the same for T8 (8 months). The level of mineralized tissue
gain was stated as the secondary outcome of this study.
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2.8. Randomization Procedure
The patients were assigned into three groups (CG, G1, or G2) by a randomized procedure.
Randomization was performed using specific software, available at http://www.randomization.com//.
2.9. Statistical Analysis
The Kruskal-Wallis test was used to analyze all groups and when a statistical difference was
verified, the Wilcoxon test was used for pairwise comparisons. Differences between mean values
were analyzed on SAS (Statistical Analysis System, NC, USA) software version 9.1.3 at p < 0.05.
Post hoc sample power calculations were performed on G*Power 3.1 (University of Düsseldorf,
Düsseldorf, Germany).
3. Results
All patients were able to receive implants and a Branemark’s rehabilitation protocol. No
complications were observed, neither at the recipient bed nor at the bone marrow’s donor site. The
histomorphometric analysis revealed that CG had the lowest percentages of VMT (36.58 ± 9.56%),
whereas G1 and G2 showed similar levels of vital hard tissue gain (55.64 ± 2.83% and 55.30 ± 1.41%,
respectively). The opposite effect was observed for NMT, where the highest percentages of soft tissue
were recorded for CG, followed by G1 and G2, with the latter two groups showing no significant
difference between each other (Table 1). A similar pattern was observed for NVMT, with highest values
recorded for CG, followed by equivalent percentages between G1 and G2 (Table 1).
Table 1. Histomorphometric results in percentage (%).
CG G1 G2
VMT 36.58 ± 9.56a 55.64 ± 2.83A 55.30 ± 1.41A
NMT 51.21 ± 11.54a 39.76 ± 10.33A 40.3 ± 11.48A
NVMT 11.16 ± 2.37a 3.65 ± 0.87A 4.10 ± 0.41A
CG: Control group; G1: Group bone marrow; G2: group bone marrow and hyperbaric oxygenation; VMT: vital
mineralized tissue; NMT: Non-mineralized tissue and NVMT: Non-vital mineralized tissue. Values followed by
different lowercase letters in the same row indicate a significant difference (Kruskal-Wallis, p < 0.05). Values followed
by different capital letters in the same column indicate a significant difference (Wilcoxon Mann-Whitney U test,
p < 0.05).
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The post hoc sample power achieved in the pairwise comparisons that revealed a significant
difference between groups was higher than 99.9%, based on 8 patients per group (Table 2).
Table 2. Achieved power, Wilcoxon Mann-Whitney U test (n = 8).
Effect Size Non-Centrality Parameter (δ) Power Achieved (%)
VMT
CG vs. G1 2.703 5.283 99.90 *
CG vs. G2 2.739 5.354 99.90 *
G1 vs. G2 0.152 0.297 8.60
NMT
CG vs. G1 0.994 1.944 57.80
CG vs. G2 0.947 1.852 54.40
G1 vs. G2 0.047 0.091 5.90
NVMT
CG vs. G1 4.206 8.221 100.00 *
CG vs. G2 3.954 7.729 100.00 *
G1 vs. G2 0.517 1.010 24.60
High sample power (*) found in the pairwise comparisons that reached statistical significance (critical t = 1.768,
D.F. = 13.278). CG: Control group; G1: Group bone marrow; G2: group bone marrow and hyperbaric oxygenation;
VMT: vital mineralized tissue; NMT: Non-mineralized tissue and NVMT: Non-vital mineralized tissue.
The tomographic evaluation did not reveal significant differences between the groups, either at
4 months or at the 8 months postoperatively (Table 3).
Table 3. Mean values of bone gain in millimeters measured on CT scans.
4 Months 8 Months
CG 4.17 ± 0.37ab 4.01 ± 0.86 ab
G1 3.85 ± 0.50ab 3.83 ± 0.27ab
G2 3.83 ± 0.73ab 3.57 ± 0.49ab
CG: Control Group; G1: Group bone marrow; G2: group bone marrow and hyperbaric oxygenation; 8 months: mean
value obtained from the formula T4–T0; 8 months: mean value obtained from the formula T8–T0. Values followed
by different lowercase letters on the same line indicate a significant difference (Kruskal-Wallis, p < 0.05). Values
followed by different capital letters in the same column indicate a significant difference (Wilcoxon Mann-Whitney
U test, p < 0.05).
4. Discussion
Teeth loss leads to alveolar bone resorption, which may hinder implant-supported dental
rehabilitation. In such context, bone grafting procedures play a vital role in recovering mineralized
tissue for implant anchorage, which was demonstrated in the 3 groups evaluated in the present
study, where all patients were successfully rehabilitated by implant supported prosthesis. Among
the options for bone grafting, autologous bone blocks are still regarded as the gold standard for
volume gain, especially in areas of critical bony defects, such as those included in the present
study. Autologous grafting does not elicit adverse immunological reactions; instead, it features
osteoconduction, osteoinduction, and osteogenesis, which are regarded as the main positive predictive
factors for graft incorporation [16,17]. Conversely, the morbidity associated with such an approach,
as well as the limited availability of adequate donor sites, have led to an ongoing search for bone
substitutes with similar characteristics [18].
Alternative biomaterials to autologous bone, whether homogenous, xenogeneic, or synthetic, are
acellular, and therefore, not recognized as osteogenic. Consequently, such biomaterials alone are not as
effective as autologous grafts for regenerative procedures, unless combined with potentially osteogenic
factors, such as BMAC, which has been showing promising results in terms of vital bone and/or
mineralized tissue gain [19,20]. In this context of combining biomaterials for bone reconstructions,
the added benefit of hyperbaric oxygenation (HBO) has not been reported, as far as the authors are
aware. Hypothetically, an increase in neovascularization and oxygenation at the grafted site could
maximize the regenerative outcome. Therefore, as BMAC has been proven useful in bone regeneration
by histomorphometry analysis, G2 group was investigated in the present study to test whether
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hyperbaric oxygenation could act synergistically to BMAC producing even higher levels of neoformed
bone. In this study, two methods of evaluation were used, CT exams and histomorphometric analysis.
For both postoperative follow-up evaluations concerning the CT exams (4 months and 8 months),
hard tissue gain was similar between groups (p > 0.05). This finding corroborates the study by
Pelegrine et al. (2016) [21], who demonstrated a significant gain in hard tissue, also evaluated by
CT exams, when comparing a bone xenograft alone against the same biomaterial associated with
BMAC, reporting gains of 4.34 ± 1.58 mm and 4.09 ± 1.33 mm, respectively, 8 months postoperatively.
Nissan et al. (2011) [22] also reported similar bone gain levels using homologous bone in appositional
grafting. Furthermore, the preclinical trial by Pelegrine et al. (2011) [23] found no significant differences
in vertical gain, when comparing homologous biomaterial (HB), HB combined with fresh bone marrow
and autologous grafts. Based on the reports, the lack of significant difference between groups presented
herein, concerning the appositional gain evaluated by CT exams, does not come as a surprise.
Regarding the histomorphometric analysis, significant differences were observed between CG and
the two test groups (i.e., G1 and G2), though no difference was detected between G1 and G2 (Table 1).
These results reiterate that the association of BMAC to a xenogeneic graft optimizes bone neoformation
(VMT), though HBO did not bring any added benefit. VMT levels in the CG were equivalent to those
reported by Oliveira et al. (2016) [24], who also used xenogeneic bone grafts. The superior results
for the variable VMT in the groups where BMAC was used (i.e., G1 and G2), may be justified by the
presence of potentially osteogenic cells and growth factors in the bone marrow, as reported by Soltan
et al. (2009) [25]. The benefits of combining BMAC with a particulated xenograft, concerning new bone
formation, was previously demonstrated for both inlay [26] and onlay [21] bone grafts. The levels of
mineralized and non-mineralized tissue presented in the previous study of Pelegrine et al. (2016) [21],
were similar with the results showed in this study.
There may be two plausible explanations for the disappointing contribution of HBO to VMT
gain. The first is a lack of effectiveness of HBO on non-infected hard tissue, as the scientific
evidence supporting a positive role of hyperbaric oxygen on healing involves mostly soft tissues
in situations of extreme hypoxia [27–29]. There is evidence in the literature that HBO may be
useful to treat osteomyelitis [30,31], which could somewhat dampen the strength of this first theory,
though osteomyelitis is associated with intense infection, which is an altogether different scenario to
guided tissue regeneration for implant supported dental rehabilitation. HBO has been reported as an
antimicrobial approach even in cases of infected bone [32], which demonstrates its positive impact on
hard tissue, though secondary to resolution of a pre-existing infectious process, as opposed to a direct
impact on germ-free bone neoformation. The second theory suggested by the authors was that HBO
had no effect on bone neoformation because it was associated with BMAC, which is already known to
promote a significant increase in neovascularization, an aspect that might not be further enhanced by
HBO. To confirm this second theory, a fourth experimental group would have been necessary, in which
the xenograft would be associated to HBO alone, without BMAC. If, in this case, HBO did maximize
the results in terms of VMT, it could be concluded that it had a positive impact on bone healing.
The CG, in addition to presenting the lowest levels of VMT, had the highest levels of NMT
and NVMT when compared to G1 and G2 (Table 1). This may be related to an acceleration of the
healing process in groups where BMAC was used (G1 and G2), which corroborates the findings on
VMT, since higher levels of bone neoformation are commonly related to higher levels of biomaterial
resorption. Such histomorphometric differences between the groups, despite a lack of quantitative
equivalence with the CT readings, represent a qualitative superiority of groups in which BMAC was
used. According to Yamada et al. (2012) [33], the quality of the regenerated tissue after 6 months of
grafting may drop by 50% in terms of mechanical strength when compared to native bone, which,
according to the authors, is an evidence of a more fragile tissue in which implant stability could
be compromised. Therefore, though no formal mechanical strength testing was performed on the
regenerated tissue in the present study, one may speculate that the presence of higher levels of vital
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mineralized tissue and lower levels of non-mineralized tissue in G1 and G2 might be surrogate markers
of implant stability, which could be the focus of forthcoming research.
The sample population that composed the study groups (n = 8) tested herein proved to be highly
robust (Table 2) for the main variable analyzed, namely histomorphometry of VMT. Larger sample
populations, are therefore, unlikely to generate a different outcome for such variable and increased
sample size ought to be discouraged based on the principles of bioethics of human experimentation.
However, it is important to state that the follow-up of this study is short, and therefore, long-term
results may be checked in the future. Despite this, it is also of major importance to state that the
results presented in this paper may have important clinical implications, especially in situations of
severe horizontal bone loss. In these situations, as most of the implant surface would be in contact
with a newly formed tissue presented after a grafting procedure, higher amounts of vital mineralized
tissue would be desirable. Therefore, the usage of BMAC would be clinically acceptable, as it can
maximize bone formation. The indication of a cell therapy approach for situations of severe atrophy
was weighted in a recent guideline for horizontal bone augmentation (i.e., HAC 4) [34].
As far as the authors are aware, this is the first randomized controlled trial evaluating the
association of cell therapy with hyperbaric oxygenation in bone grafting for implant supported
dental rehabilitation. In view of the findings presented herein, the use of bone marrow aspirate
concentrate favored bone regeneration, though hyperbaric oxygenation did not provide any added
benefit. However, it is important to highlight that different study designs should be considered to
isolate variables to ascertain the benefit of HBO over BMAC.
5. Conclusions
Appositional bone reconstruction using block xenograft associated with bone marrow aspirate
concentrate resulted in a significant increase of newformed bone than the xenograft alone, though the
use of hyperbaric oxygenation did not enhance the results.
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